Development asset linked to Medicenna Therapeutics in public FDA and regional records.
pharma · Advanced Solid Tumors · Advanced Solid Tumor · MDNAF
Medicenna Therapeutics
Medicenna Therapeutics drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Toronto, CA HQ
24 Employees
Public company Type
MDNAF · NYSE Ticker
Company details
- Status
- Public
- HQ
- Toronto, CA
- Employees
- 24
- Programs
- 3
- Drugs
- 3
- Patents
- 9
Medicenna Therapeutics pipeline
Portfolio lens on 3 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Medicenna Therapeutics drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
pembrolizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
Development asset linked to Medicenna Therapeutics in public FDA and regional records.